Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
- Conditions
- First Posted Date
- 2004-05-31
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00083707
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
- Conditions
- First Posted Date
- 2004-05-31
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 25
- Registration Number
- NCT00083694
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
- Conditions
- First Posted Date
- 2004-05-28
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 180
- Registration Number
- NCT00083681
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
- Conditions
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00083538
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 250
- Registration Number
- NCT00083577
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 668
- Registration Number
- NCT00083551
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2018-06-26
- Target Recruit Count
- 44
- Registration Number
- NCT00006358
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2010-08-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 86
- Registration Number
- NCT00083460
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Conditions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 20
- Registration Number
- NCT00083408
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Conditions
- Interventions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 83
- Registration Number
- NCT00083382
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.